[ad_1]
A team of researchers at the University of Manchester has shown that a new clbad of drugs can stop the growth of ovarian cancer cells.
The study funded by Cancer Research UK and Wellcome Trust, published in the journal Cancer cell, have shown that drugs, called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses in their ability to copy their DNA.
The PDD00017273, PARG's first inhibitor, was discovered in the drug discovery unit of Cancer Research UK Manchester Institute, which is part of the University of Manchester, as part of a program targeted to discover PARG inhibitors for the clinic.
This program is currently advancing through collaboration with IDEAYA Biosciences, Inc., an oncology-focused biotechnology company engaged in breakthrough drug discovery of lethality and immuno-oncology therapies.
These findings are promising for patients with ovarian cancer, the sixth leading cause of cancer among women in the UK, and causing more than 4,000 deaths a year.
"Unfortunately, for the majority of women diagnosed with ovarian cancer, the cancer recurs within 12 to 18 months of their first treatment, so there is an urgent need to develop new treatments to treat this condition. disease, "said lead professor Stephen Taylor, scientist, University of Manchester.
Thanks to a collaboration between the University of Manchester, including Cancer Research UK Manchester Institute and Christie (Manchester), scientists have been able to detect ovarian cancer genes for specific genes that, once eliminated, would lead to sensitivity to PARG inhibitors. Through their work, the team identified the key genes that made cancer cells sensitive to PDD00017273 were those involved in DNA replication.
PhD student Nisha Pillay provided valuable insights into how PARG inhibitors work. She said, "Before a cell divides, it must replicate its DNA.This critical process ensures the transmission of the necessary amount of DNA to its daughter cells." Our research has shown that one inherent defect in the ability of an ovarian cancer cell to replicate its DNA can be exploited by the PARG inhibitor to kill the cancer cell ".
"This new clbad of drugs is potentially very exciting and could be a new way to help patients with diagnosed ovarian cancer for whom their tumor has not responded to treatment." standard".
The research team then showed that the PARG inhibitor could also be used in combination with other clinically-accessible drugs, such as the inhibitors of CHK1 and WEE1, to kill cancer cells. ovary collected directly from samples taken from patients treated with Christie.
Dr. Robert Morgan, of The Christie, said: "We hope that this work will give an additional impetus to the development of a PARG inhibitor that can be used in human trials, as well as biomarkers that can be used to select the most appropriate patients to receive such treatments in the future. "
###
NOTES TO EDITORS
References:
Pillay & Tighe et al. Vulnerabilities related to DNA replication make ovarian cancer cells susceptible to inhibitors of poly (ADP-ribose) glycohydrolase. Cancer cell (in the press)
Teacher. Taylor, Nisha Pillay, Dr. Morgan are available to comment
Pillay & Tighe et al. Vulnerabilities related to DNA replication make ovarian cancer cells susceptible to inhibitors of poly (ADP-ribose) glycohydrolase. Cancer cell is available on request
This work was funded by Cancer Research UK and the Wellcome Trust.
For media inquiries, contact:
Mike Addelman
Media Relations Officer
Faculty of Biology, Medicine and Health
University of Manchester
0161 275 2111
07717 881567
[email protected]
Warning: AAAS and EurekAlert! are not responsible for the accuracy of the news releases published on EurekAlert! contributing institutions or for the use of any information via the EurekAlert system.
Source link
